Home Clinical Topics FDA approves Promacta for pediatric patients with chronic ITP

FDA approves Promacta for pediatric patients with chronic ITP

On Aug. 24, the U.S. Food and Drug Administration (FDA) approved Promacta (eltrombopag) to treat chronic immune thrombocytopenic purpura (ITP) in pediatric patients (ages one year and older). Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here